Related Experiment Video
Updated: Aug 2, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 5, 2010
The potential impact of palivizumab on pediatric airway reconstruction
Kevin Emerick1, Michael Cunningham, Christopher Hartnick
1Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA.
Insights
Palivizumab may reduce serious complications from respiratory syncytial virus (RSV) in pediatric airway surgery. Cost is a barrier, but otolaryngologists should consider its prophylactic use in high-risk patients.
Area of Science:
- Pediatric Surgery
- Infectious Disease Prevention
- Pharmacology
Background:
- Respiratory syncytial virus (RSV) poses significant risks in surgical settings.
- Postoperative complications from RSV infection can lead to severe morbidity and mortality.
Purpose of the Study:
- To evaluate palivizumab's role in preventing RSV in pediatric airway reconstruction.
- To assess the medical benefit and cost-effectiveness of palivizumab in this patient group.
Main Methods:
- Literature review of MEDLINE database for studies on RSV, palivizumab, and airway reconstruction.
- Inclusion of Phase IV trials and studies on postoperative outcomes complicated by RSV.
Main Results:
- RSV infection causes substantial postoperative morbidity and mortality across surgical specialties.
- Perioperative palivizumab shows potential benefit, but cost is a major limitation.
Conclusions:
- Otolaryngologists should consider palivizumab prophylaxis for pediatric airway reconstruction patients during high-risk RSV seasons.
- Further multicenter studies are needed for a comprehensive cost-benefit analysis.
Purpose:
To examine the role of palivizumab, a monoclonal antibody vaccine designed to prevent respiratory syncytial virus (RSV) infection, in the surgical setting, and to explore the feasibility, in terms of medical benefit and cost, of its use in pediatric airway reconstruction patients.
Materials And Methods:
Literature review of MEDLINE database using the following indexing terms ("respiratory syncytial virus," "palivizumab," "laryngotracheal reconstruction," and "cricotracheal reconstruction") and limited to following subcategories (English language, postoperative complication, and morbidity and mortality). All phase IV clinical trials reporting data regarding safety, efficacy, and application of palivizumab in the general pediatric population were selected, as well as all studies from any surgical specialty with data on postoperative outcome complicated by RSV infection.
Results:
The literature demonstrates significant postoperative morbidity and mortality attributable to RSV infection within several surgical specialties including otolaryngology. Meta-analysis of the data from phase IV clinical trials suggests potential benefit from the perioperative use of palivizumab. The cost of vaccination is the principal limiting factor preventing its more widespread application.
Conclusion:
Otolaryngologists need to be aware of the potential significant morbidity caused by perioperative RSV infection and should consider the prophylactic use of palivizumab in their pediatric airway reconstruction patients in high-risk seasons. A large multicenter study would be required to adequately perform a cost-benefit analysis of palivizumab use for this specific indication.
More Related Videos
10:15Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
Published on: March 22, 2017
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
